Sheehan, et al., have also reported that claudin-3 expression correlates with advanced stage and tumor recurrence in prostate cancer [21], which coincides with another study of urothelial carcinoma, where claudin-3 has also been shown to correlate with advanced stage and poor survival[26]. Here, CLDN3 is linked to prostate cancer.